Comparison of chemotherapeutic combination therapy, dosing frequency and dosing sequence for the adjuvant treatment of early-stage breast cancer: a network meta-analysis - PubMed
4 hours ago
- #network meta-analysis
- #chemotherapy regimens
- #breast cancer
- The network meta-analysis evaluated 36 randomized controlled trials involving 17,187 patients to compare chemotherapeutic regimens for adjuvant treatment of early-stage breast cancer.
- Regimen AQ (six cycles of taxane + cyclophosphamide every three weeks) ranked highest for event-free survival (SUCRA: 0.95).
- Regimen AF (four cycles of doxorubicin followed by taxane) showed the highest probability for overall survival (SUCRA: 0.92).
- AQD regimen was associated with the lowest incidence of nausea, and regimen C had the lowest risk of neutropenia among the studied treatments.
- Concurrent six-cycle taxane and cyclophosphamide at three-week intervals was identified as the optimal adjuvant therapy for early-stage breast cancer.